Close Menu

NEW YORK (GenomeWeb) – In a preliminary analysis of a two-month promotion where it offered free hereditary cancer screening, Counsyl has found that nearly half of women who have tested positive did not meet criteria for screening.

The company told GenomeWeb that as of mid-November, more than 1,500 women had taken advantage of the initiative, called Get Ahead of Cancer, where it offered its 22-gene hereditary cancer panel free of charge during October and November to women in the San Francisco Bay Area.   

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

GenomeWeb Premium gives you:
✔ Full site access
✔ Interest-based email alerts
✔ Access to archives

Never miss another important industry story.

Try GenomeWeb Premium now.

You may already have institutional access!

Check if I qualify.

Already a GenomeWeb or 360Dx Premium member?
Login Now.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.

Following discrimination allegations, NICHD's Constantine Stratakis withdraws from a new position at the Research Institute of the McGill University Health Center, Science reports.

US President Donald Trump has threatened to cut World Health Organization funding over its pandemic response, which would affect its ability to do its work and which he might not be able to do.

The US Securities and Exchange Commission has halted the sales of a handful of stocks over claims made about the coronavirus.

In Nature this week: comparative analyses of single-cell RNA sequencing protocols uncover differences between approaches, and more.

May
06
Sponsored by
Isoplexis

This webinar will discuss the application of single-cell proteomics and immune-imaging in adoptive cell therapy (ACT) for cancer.

May
19
Sponsored by
10x Genomics

Uveal melanoma (UM) is a highly metastatic cancer that, in contrast to cutaneous melanoma, is largely unresponsive to checkpoint immunotherapy.